JBS NV Q2 EPS of $0.20 Misses Estimates Despite 84/100 GF Score Valuation Signal
JBS NV reported Q2 EPS of $0.20, falling short of analyst estimates in a disappointing quarter
TLDR
- โJBS NV reported Q2 EPS of $0.20, falling short of analyst estimates in a disappointing quarter
- โGuruFocus assigns JBS a GF Score of 84/100, suggesting the stock may be undervalued relative to its fundamentals
- โThe earnings miss highlights near-term protein sector headwinds despite a constructive long-term valuation case
Editorial Self-Reviewยท70/100Review tier
- Specific EPS ($0.20) and GF Score (84/100) provide quantitative anchors
- Cattle cycle and BRL hedge mechanism correctly identified
- Single tier-3 source; specific revenue figures and prior-period comparison not available
Why this matters
Coverage sentiment: Neutral (0 bullish ยท 1 neutral ยท 0 bearish)
JBS operations in India are limited, but its global protein market influence affects Indian poultry and beef export pricing; JBS quarterly results are a leading indicator for global meat processing margins that affect Indian exporters.
What to watch
- โข JBS Q3 US beef segment guidance โ cattle supply normalization timeline is the key earnings recovery catalyst
- โข USDA cattle inventory report โ quarterly data on US cattle herd size drives medium-term supply and margin trajectory for meatpackers
Ripple effects
- โข Tyson Foods, Smithfield โ US peer processors face similar cattle supply cycle headwinds; JBS miss confirms sector-wide margin pressure is real
AI-Synthesized news from multiple sources
This article was synthesized by AI from the source articles listed below, reviewed by a second-pass AI quality reviewer, and published by the market.news editorial system. How we do this ยท Editorial standards ยท Report an error
The Quick Take
- JBS NV reported Q2 EPS of $0.20, falling short of analyst estimates in a disappointing quarter
- GuruFocus assigns JBS a GF Score of 84/100, suggesting the stock may be undervalued relative to its fundamentals
- The earnings miss highlights near-term protein sector headwinds despite a constructive long-term valuation case
JBS NV's Q2 EPS of $0.20 missing consensus estimates adds another data point to a challenging year for the world's largest meat processing company. JBS, which processes beef, pork, and poultry across Brazil, the US, Australia, and Europe, faces the complex task of navigating regional protein market cycles simultaneouslyโwhen US beef margins are under pressure, Brazilian operations may be compensating, and vice versa. A Q2 earnings miss despite the company's global scale and diversification signals that at least one major regional market faces meaningful margin compression, likely from cattle cycle dynamics or input cost pressures that haven't fully normalized.
The GF Score of 84/100 from GuruFocus suggests that despite the earnings miss, the stock's quantitative profile on financial strength, profitability, growth, and valuation metrics remains constructive. A high GF Score typically indicates a company trading below intrinsic value relative to its fundamental quality indicatorsโa situation that can attract value-oriented institutional investors if the earnings miss is perceived as cyclical rather than structural. In the global meat processing peer group, Tyson Foods, Smithfield, and NH Foods (Japan) all share similar cyclical earnings dynamics, making sector-wide repricing events like the current period potentially attractive for multi-year accumulation strategies.
The key diagnostic is whether JBS's Q2 miss reflects cattle cycle timing (a recoverable headwind) or structural margin compression from increased competition, retailer pricing power, or regulatory cost burdens. Watch the Q3 guidance for the US beef segmentโcattle supplies in the US are at a cyclical low after several years of herd liquidation, which compresses meatpacker margins but should reverse as herd rebuilding eventually tightens supply. The macro variable is Brazil's BRL/USD rate: JBS Brazil operations reporting in BRL translate to more USD earnings when BRL strengthens, providing a natural hedge against US beef cycle weakness. Currency trajectory and Selic rate policy are therefore second-order earnings drivers for JBS.
Synthesized from 1 source.
Market Intelligence Panel
Sentiment
NeutralCoverage
livesource covering this story
Live Price
JBS๐ Key Numbers
๐ India / Asia Angle
JBS operations in India are limited, but its global protein market influence affects Indian poultry and beef export pricing; JBS quarterly results are a leading indicator for global meat processing margins that affect Indian exporters.
๐ Ripple Effects
- โธTyson Foods, Smithfield โ US peer processors face similar cattle supply cycle headwinds; JBS miss confirms sector-wide margin pressure is real
- โธBrazilian BRL โ JBS's significant Brazilian operations make its earnings sensitive to BRL/USD rate; currency move has earnings multiplier effect
- โธUS cattle ranchers โ JBS meatpacker margins reflect farm-gate cattle prices; low JBS margins suggest competition for cattle supply is pressuring processing economics
๐ญ What to Watch Next
PRO- โธJBS Q3 US beef segment guidance โ cattle supply normalization timeline is the key earnings recovery catalyst
- โธUSDA cattle inventory report โ quarterly data on US cattle herd size drives medium-term supply and margin trajectory for meatpackers
- โธBRL/USD rate โ Brazilian real strengthening is a tailwind for JBS's USD-reported earnings from South American operations
Market news synthesis. Not financial advice. Sources cited above.
How the Story Spread
1 publisher covering this story
AI synthesis of every source listed below. Tier 1 = wire services (AP, Reuters via wire, Bloomberg, official central banks). Tier 2 = major financial publishers. Tier 3 = niche / specialist outlets. Click any card to read the original article.
Get the Daily Briefing
Pre-market analysis every morning at 6am ET. Free.
Was this article useful?
Anonymous ยท helps us tune the editorial system
More ๐บ๐ธ United States Stories
Cardinal Health Q4 GAAP EPS Misses at $1.70 vs $2.04 Estimate With $63.7 Billion in Revenue
Cardinal Health (CAH) reported Q4 fiscal 2026 results with GAAP EPS of $1.70 falling short of analyst estimates near $2.04, while quarterly revenue reached $63.7 billion โ reflecting margin compression challenges facing large pharmaceutical distributors.
Aug 12, 2026
๐บ๐ธ United StatesQ2 Earnings Roundup: Venture Global Posts $4.6B Revenue While Kopin, Broadwind, Microvast, Aeries All Miss
A wave of Q2 2026 earnings reports from small-cap U.S. stocks revealed mixed results: Venture Global (VG) delivered $4.6 billion in revenue while Kopin Corp (KOPN), Broadwind (BWEN), Microvast (MVST), and Aeries Technology (AERT) all reported earnings misses.
Aug 12, 2026
๐บ๐ธ United StatesAutolus Therapeutics AUCATZYL Q2 Revenue Surges 119%; Full-Year 2026 Outlook Raised
Autolus Therapeutics (AUTL) reported Q2 2026 revenue surging 119% for its AUCATZYL CAR-T cell therapy, and raised its full-year 2026 revenue outlook on stronger-than-expected commercial uptake.
Aug 12, 2026